Hormone-Resistant Prostate Cancer Clinical Trial
Official title:
A Selective Frontline Cabazitaxel Therapeutic Pathway for Castration-Resistant Prostate Cancer With Integrated Biomarkers
Verified date | January 2021 |
Source | University of California, Davis |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well cabazitaxel and prednisone work in treating patients with hormone-resistant prostate cancer that has spread to other parts of the body. Drugs used in chemotherapy, such as cabazitaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Status | Terminated |
Enrollment | 2 |
Est. completion date | June 4, 2019 |
Est. primary completion date | June 4, 2019 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed prostate adenocarcinoma - Metastatic disease - Able and willing to provide informed consent and to comply with the study procedures - Castration resistant disease defined as evidence of radiological and/or prostate specific antigen (PSA) progression despite castrate levels of testosterone (serum testosterone < 50 ng/dL [1.7 nmol/L]); for PSA progression, there must be at least 2 sequential rises at a minimum of 1-week intervals; the first PSA value must be >= 4 (Prostate Cancer Working Group 2 [PCWG2] criteria) - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - At least 21 days have passed since completing radiotherapy (exception for radiotherapy: at least 7 days since completing a single fraction of =< 800 cGy to a restricted field or limited-field radiotherapy to non-marrow bearing area such as an extremity or orbit) at the time of registration - At least 21 days have passed since receiving any investigational agent at the time of registration - At least 21 days have passed since major surgery - Neuropathy =< grade 1 at the time of registration - Has recovered from all therapy-related toxicity to =< grade 2 (except alopecia, anemia and any signs or symptoms of androgen deprivation therapy) at the time of registration - Poor prognosis disease as defined by any of the following: - PSA nadir >=4.0, or - Gleason score 8-10, or - Time from ADT initiation to CRPC of =< 16 months - Hemoglobin >= 90 g/L - Neutrophils >= 1.5 x 10^9 /L - Platelets >= 100 x 10^9/L - Aspartate aminotransferase (AST) < 1.5 x upper limit of normal (ULN) - Alanine aminotransferase (ALT) < 1.5 x ULN - Bilirubin =< 1.0 x ULN (exceptions for Gilbert's syndrome) - Creatinine =< 1.5 x ULN Exclusion Criteria: - Prior therapy with cabazitaxel or to other drugs formulated with polysorbate 80 - Prior taxanes for CRPC - Prior enzalutamide, abiraterone or ketoconazole - Other condition, illness, psychiatric condition, or laboratory abnormality that may increase the risk associated with administration of cabazitaxel, study participation, or may interfere with the interpretation of study results and in the judgment of the investigator would make the patient inappropriate for entry into this study - Histologic evidence of small cell/neuroendocrine prostate cancer - Patients with reproductive potential who do not agree to use accepted and effective method of contraception during the study treatment period and up to 6 months after the last administered dose; the definition of "effective method of contraception" will be based on the investigator's judgment |
Country | Name | City | State |
---|---|---|---|
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
University of California, Davis | Sanofi |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | PSA Response Rate, Defined as >= 50% Decline in PSA From Baseline Maintained for at Least 3 Weeks and Measured by the Same Laboratory, and Without Evidence of Other Disease Progression Documented at Time of Confirmatory Values | The response rate will be compared to a historical response rate of 20% using the exact binomial test for a single proportion. Confidence intervals for the response rate will be calculated using Wilson's method. | Up to 18 months. | |
Secondary | Incidence of Adverse Events, Serious Adverse Events, and Discontinuations, Described and Graded According to the National Cancer Institute Common Terminology Criteria for Adverse Events Version 4.03 | Incidence of adverse events, serious adverse events, and discontinuations, described and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.03 | Up to 28 days after discontinuation of study drug | |
Secondary | Overall Survival (OS) Defined as the Time Interval From the Date of Enrollment to the Date of Death Due to Any Cause. | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. | Up to 18 months. | |
Secondary | Progression-free Survival (PFS) Defined as the Time Interval Between the Date of Enrollment and the Date of the First Documentation by the Prostate Cancer Working Group 2 (PCWG2) Criteria. | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. | Approximately 5 months. | |
Secondary | Response Evaluation Criteria in Solid Tumors (RECIST) Response Defined as Radiographic Disease Progression | Confidence intervals for the response rate will be calculated using Wilson's method. Medians will be estimated using the method of Kaplan and Meier, with confidence intervals estimated using Greenwood's method. | Approximately 5 months. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02491411 -
Dexamethasone Prior to Re-treatment With Enzalutamide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Enzalutamide and Docetaxel
|
N/A | |
Active, not recruiting |
NCT01685125 -
Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT00936975 -
Fluorine F 18 Sodium Fluoride Positron Emission Tomography in Evaluating Response to Dasatinib in Patients With Prostate Cancer and Bone Metastases
|
Phase 2 | |
Active, not recruiting |
NCT00486642 -
Pazopanib Hydrochloride With or Without Bicalutamide in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
|
Phase 2 | |
Terminated |
NCT02215161 -
Selinexor in Treating Patients With Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01866423 -
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Completed |
NCT01468532 -
Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01026623 -
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer
|
Phase 1/Phase 2 | |
Terminated |
NCT02985021 -
Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies
|
Phase 2 | |
Completed |
NCT01240629 -
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT02312557 -
Pembrolizumab in Treating Patients With Metastatic Castration Resistant Prostate Cancer Previously Treated With Enzalutamide
|
Phase 2 | |
Active, not recruiting |
NCT01953640 -
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
|
||
Completed |
NCT00040755 -
BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy
|
Phase 2 | |
Withdrawn |
NCT02966587 -
Durvalumab in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
|
Phase 2 | |
Terminated |
NCT01093183 -
Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01812668 -
Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
|
N/A | |
Completed |
NCT01522820 -
Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors
|
Phase 1 | |
Recruiting |
NCT03979339 -
Feasibility of a New Technology for Isolating Circulating Tumour Cells
|
N/A | |
Completed |
NCT01807065 -
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
|
Phase 2 | |
Withdrawn |
NCT02567396 -
Talazoparib in Treating Patients With Advanced or Metastatic Solid Tumors That Cannot Be Removed by Surgery and Liver or Kidney Dysfunction
|
Phase 1 |